NO20080259L - Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet - Google Patents

Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet

Info

Publication number
NO20080259L
NO20080259L NO20080259A NO20080259A NO20080259L NO 20080259 L NO20080259 L NO 20080259L NO 20080259 A NO20080259 A NO 20080259A NO 20080259 A NO20080259 A NO 20080259A NO 20080259 L NO20080259 L NO 20080259L
Authority
NO
Norway
Prior art keywords
complement system
epithelial cells
extracellular matrix
interactions
moraxella catarrhalis
Prior art date
Application number
NO20080259A
Other languages
English (en)
Inventor
Arne Forsgren
Kristian Riesbeck
Original Assignee
Arne Forsgren Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arne Forsgren Ab filed Critical Arne Forsgren Ab
Publication of NO20080259L publication Critical patent/NO20080259L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Sammendrag Det beskrives ekstracellulære matriksproteiner av Moraxella catarrhalis og deres evne til å interagere med epiteliske celler via celleassosiert fibronektin og laminin, og også deres evne t il å inhibere komplementsystemet. Disse ekstracellulære proteiner er nyttige i fremstilling av vaksiner. Det beskrives også peptider som interagerer med fibronektin, laminin og komplementsystemet.
NO20080259A 2005-08-10 2008-01-14 Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet NO20080259L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70674505P 2005-08-10 2005-08-10
US70714805P 2005-08-11 2005-08-11
PCT/SE2006/000931 WO2007018463A2 (en) 2005-08-10 2006-08-08 Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system

Publications (1)

Publication Number Publication Date
NO20080259L true NO20080259L (no) 2008-05-13

Family

ID=37727738

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080259A NO20080259L (no) 2005-08-10 2008-01-14 Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet

Country Status (15)

Country Link
US (7) US8092811B2 (no)
EP (4) EP2548885B1 (no)
JP (2) JP5269594B2 (no)
KR (1) KR20080042865A (no)
AU (1) AU2006277076B2 (no)
BR (1) BRPI0614734A2 (no)
CA (1) CA2618554C (no)
EA (1) EA014352B1 (no)
ES (1) ES2537274T3 (no)
IL (2) IL189258A0 (no)
MA (1) MA29765B1 (no)
MX (1) MX2008002037A (no)
NO (1) NO20080259L (no)
NZ (1) NZ565651A (no)
WO (1) WO2007018463A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014352B1 (ru) * 2005-08-10 2010-10-29 Арне Форсгрен Аб Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
EA201391669A1 (ru) * 2011-05-11 2014-04-30 Риесбекк Хелткеэр Свиден Аб Белок f - новый адгезин haemophilus influenzae, способный связывать ламинин и витронектин
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
JP2020515587A (ja) 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 免疫原性組成物、使用及び処置方法
WO2019034575A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa METHODS OF AMPLIFYING IMMUNE RESPONSES
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CA3148928A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
WO2021048159A1 (en) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Assay
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
CN114409756B (zh) * 2022-01-21 2023-06-09 中国科学院海洋研究所 一种牙鲆补体成分C3（PoC3）的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) * 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
CN1159441C (zh) * 1996-12-20 2004-07-28 德克萨斯州大学系统董事会 粘膜炎莫拉菌的uspa1和uspa2抗原
GB0003502D0 (en) 2000-02-15 2000-04-05 Smithkline Beecham Sa Vaccine
DK2088197T3 (en) 2000-10-02 2016-08-01 Id Biomedical Corp Quebec Haemophilus influenzae antigens and corresponding DNA fragments
SE0102410D0 (sv) 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
EP1409013B1 (en) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0222764D0 (en) 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EA014352B1 (ru) 2005-08-10 2010-10-29 Арне Форсгрен Аб Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
CN104436180B (zh) 2006-01-17 2021-08-31 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)

Also Published As

Publication number Publication date
US20100062027A1 (en) 2010-03-11
WO2007018463A3 (en) 2007-05-10
KR20080042865A (ko) 2008-05-15
JP5269594B2 (ja) 2013-08-21
US10183071B2 (en) 2019-01-22
US20160318979A1 (en) 2016-11-03
ES2537274T3 (es) 2015-06-05
EA014352B1 (ru) 2010-10-29
US8323667B2 (en) 2012-12-04
JP2013150614A (ja) 2013-08-08
EP1913019A2 (en) 2008-04-23
US20170281746A1 (en) 2017-10-05
IL216703A0 (en) 2012-01-31
CA2618554C (en) 2017-03-07
CA2618554A1 (en) 2007-02-15
US20190117757A1 (en) 2019-04-25
NZ565651A (en) 2012-01-12
BRPI0614734A2 (pt) 2011-04-12
US20130129763A1 (en) 2013-05-23
EP1913019B1 (en) 2014-12-31
EP2548885A2 (en) 2013-01-23
IL189258A0 (en) 2008-08-07
JP2009504152A (ja) 2009-02-05
MA29765B1 (fr) 2008-09-01
US10786562B2 (en) 2020-09-29
EP3305807B1 (en) 2024-08-21
EA200800565A1 (ru) 2008-10-30
US9657067B2 (en) 2017-05-23
US8092811B2 (en) 2012-01-10
US9255127B2 (en) 2016-02-09
EP2548884A3 (en) 2013-05-01
AU2006277076A1 (en) 2007-02-15
EP2548884B1 (en) 2017-08-02
MX2008002037A (es) 2008-03-27
EP2548885A3 (en) 2013-05-01
US8895030B2 (en) 2014-11-25
AU2006277076B2 (en) 2012-03-29
EP3305807A1 (en) 2018-04-11
JP5763113B2 (ja) 2015-08-12
EP2548885B1 (en) 2017-10-18
US20120148614A1 (en) 2012-06-14
US20150140026A1 (en) 2015-05-21
EP2548884A2 (en) 2013-01-23
WO2007018463A2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
NO20080259L (no) Interaksjoner av Moraxella catarrhalis med epitelceller, ekstracellulaere matriksproteiner og komplementsystemet
AU2019268194A1 (en) Cell culture system
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
WO2008147816A3 (en) Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof
HN2005000485A (es) PRODUCCION DE TNFR-Ig
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
CY1110734T1 (el) Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
BRPI0620648A8 (pt) variação de um domínio d3 da interleucina-12p40, proteína il-12 ou um fragmento da mesma, proteína de fusão, ácido nucléico, vetor de expressão, célula hospedeira, composição farmacêutica e uso da mesma
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
WO2007130642A3 (en) Modulation of nkg2d
EP2145953A4 (en) ACELLULAR SYSTEM FOR THE SYNTHESIS OF PROTEINS FROM CULTURED MAMMAL CELLS
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
NO20076391L (no) Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin
AR057058A1 (es) Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
WO2018120843A9 (zh) 一种三功能分子及其应用
NZ603942A (en) Vitronectin:keratinocyte growth factor chimeras
FR2911608B1 (fr) Nouvelles compositions vaccinales anti paludique et ses utilisations.
UA95456C2 (ru) Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
EP1885867A4 (en) NEW PROCEDURES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application